$CE

Celanese Corp (CE): Results of Operations and Financial Condition

Celanese Corp (CE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Celanese Corporation Reports Second Quarter Earnings Dallas, August 4, 2026: Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported second quarter 2026 U.S. GAAP diluted earnings per share of $1.15 and adjusted earnings per

Original reporting
Published Aug 4, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CE
Neutral
medium confidence
Mentioned
$CE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CENeutralLow
01

Why it matters

Because the provided content focuses on definitions and presentation rules, it is unlikely to change valuation assumptions by itself. Any trading impact would depend on whether the omitted portions contain new financial results or material changes.

02

Market read

Supplemental non-GAAP framework update for results and financial condition, with no explicit new numeric datapoints in the provided excerpt.

03

What to watch

If Exhibit 99.2 includes updated reconciliations or segment figures not shown in the scrape, the relevance could rise; the current text appears to be mostly methodology boilerplate.

Relevance 7/10Novelty 2/10Timing: filed Aug 4, 2026 (after market hours)

Background

The SEC 8-K Item 2.02 is accompanied by Exhibit 99.2 describing Celanese’s non-GAAP financial measures and how they reconcile to GAAP.

Company-level read

Ticker impact

$CENeutralMedium confidence
Context

Celanese filed an 8-K with Item 2.02 and an Exhibit 99.2 detailing its non-GAAP metrics framework for results and financial condition.

Expected impact

Limited near-term impact unless the missing tables include new financial datapoints beyond the non-GAAP definitions.

Evidence & confidence

The excerpt is dominated by definitions, purpose, and reconciliation methodology for adjusted EBIT, operating EBITDA, net debt, and free cash flow, without any new numeric results or forward-looking guidance.

Market effects

Minimal, as the excerpt does not introduce new segment performance, demand signals, or guidance.

None indicated.

None indicated.

Counterpoint

Traders may still use the updated non-GAAP definitions to interpret upcoming earnings comparisons, but the excerpt itself provides no new performance numbers.

Key entities

  • Celanese Corporation

    Subject issuer filing an 8-K (Item 2.02) with supplemental non-GAAP financial measures documentation.

Related articles

$CEMed

KeyBanc initiates Celanese stock coverage with overweight rating

KeyBanc initiated coverage on Celanese (NYSE: CE) with an overweight rating and a $57 price target, citing attractive valuation and strong free cash flow yield. The firm estimates the company has sufficient liquidity to repay debt through 2028. Celanese's Q2 2026 earnings beat estimates but revenue missed slightly, with a cautious outlook due to restructuring and leverage concerns.

$CEMed

Mitsui to Integrate Nutrinova's Upstream Materials Production and Make Nutrinova a Consolidated Subsidiary

Mitsui & Co. will integrate upstream operations at VP4, a German producer of key intermediates for Nutrinova's food ingredients. Mitsui will acquire an additional 19% stake in Nutrinova from Celanese, increasing its holding to 89% and making Nutrinova a consolidated subsidiary. This move aims to secure supply, improve cost competitiveness, and align with Mitsui's growth strategy in the Food Science business.

$CEMed

Celanese (CE) Beat Estimates, So Why Is Guidance Getting Trickier?

Celanese (NYSE:CE) beat May-set expectations in Q2 but signaled a tougher Q3 on an earnings call Aug. 4. Management attributed the swing to timing and flexing of its production network, accelerated plant shutdowns, weaker equity earnings from the Ibn Sina JV, and regional margin/volume pressures. CE kept 2026 free cash flow guidance at $700M to $800M and reiterated $1B divestitures by end-2027.

$CEMed

Celanese Corporation: Amsterdam District Court Rules in Favor of Celanese and its Co-Defendants in Shell and Repsol Cases, Dismissing All Claims

Celanese (NYSE: CE) said the Amsterdam District Court dismissed Shell Chemicals Europe’s damages claim and a Repsol entities claim seeking declaratory judgment of liability against Celanese and co-defendants. The cases stem from follow-on litigation related to a 2020 European Commission settlement over past ethylene purchases in North-Western Europe.